Nyantakyi Samuel Agyei obtained a PhD at the Department of Pharmacy of the National University of Singapore, which focused on identifying novel small molecules selectively targeting the cell membrane of Mycobacterium tuberculosis. Samuel’s core expertise is in multi-step syntheses of small molecules, analyses of structure-activity relationships to improve compound quality, and building and managing compound libraries.
Samuel joins our KI team to develop medicinal chemistry approaches to modify and improve on candidate small molecules capable of modulating the activities of various receptors, including our recently discovered compounds targeting p75NTR, based on our article in Cell Chemical Biology.